VISTAGEN THERAPEUTICS, INC. Proceeds from Securities Purchased under Agreements to Resell
VISTAGEN THERAPEUTICS, INC. (VTGN) reported Proceeds from Securities Purchased under Agreements to Resell of $3.10 million for the 12-month period ending 2015-03-31, per its 10-K filed 2015-06-29.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromSecuritiesPurchasedUnderAgreementsToResell · last filed 2015-06-29
- VISTAGEN THERAPEUTICS, INC. proceeds from securities purchased under agreements to resell for fiscal 2015 was $3.10M.
| Period end | Proceeds from Securities Purchased under Agreements to Resell 12 month |
|---|---|
| 2015-03-31 | $3.10M 10-K · filed 2015-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |